FDA Approves First PARP Inhibitor for Prostate Cancer

A new combination therapy for aggressive prostate cancer just got FDA approval, along with two tests that help doctors match the right patients to this targeted treatment.

This breakthrough could help up to 30% of men with advanced prostate cancer find a treatment plan designed specifically for their genes.